CRMD vs. ENTA, CTNM, EPIX, BDTX, XOMA, VRCA, KMDA, NBTX, VNDA, and INZY
Should you be buying CorMedix stock or one of its competitors? The main competitors of CorMedix include Enanta Pharmaceuticals (ENTA), Contineum Therapeutics (CTNM), ESSA Pharma (EPIX), Black Diamond Therapeutics (BDTX), XOMA (XOMA), Verrica Pharmaceuticals (VRCA), Kamada (KMDA), Nanobiotix (NBTX), Vanda Pharmaceuticals (VNDA), and Inozyme Pharma (INZY). These companies are all part of the "medical" sector.
CorMedix (NASDAQ:CRMD) and Enanta Pharmaceuticals (NASDAQ:ENTA) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, risk, dividends, community ranking, analyst recommendations, institutional ownership, media sentiment, profitability and earnings.
In the previous week, Enanta Pharmaceuticals had 21 more articles in the media than CorMedix. MarketBeat recorded 24 mentions for Enanta Pharmaceuticals and 3 mentions for CorMedix. CorMedix's average media sentiment score of 0.33 beat Enanta Pharmaceuticals' score of -0.02 indicating that CorMedix is being referred to more favorably in the media.
CorMedix has higher earnings, but lower revenue than Enanta Pharmaceuticals. CorMedix is trading at a lower price-to-earnings ratio than Enanta Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
CorMedix has a net margin of 0.00% compared to Enanta Pharmaceuticals' net margin of -187.77%. Enanta Pharmaceuticals' return on equity of -60.38% beat CorMedix's return on equity.
CorMedix has a beta of 1.79, suggesting that its share price is 79% more volatile than the S&P 500. Comparatively, Enanta Pharmaceuticals has a beta of 0.54, suggesting that its share price is 46% less volatile than the S&P 500.
34.2% of CorMedix shares are held by institutional investors. Comparatively, 95.0% of Enanta Pharmaceuticals shares are held by institutional investors. 3.6% of CorMedix shares are held by insiders. Comparatively, 13.6% of Enanta Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
CorMedix currently has a consensus price target of $13.00, suggesting a potential upside of 127.87%. Enanta Pharmaceuticals has a consensus price target of $19.00, suggesting a potential upside of 48.90%. Given CorMedix's stronger consensus rating and higher probable upside, analysts clearly believe CorMedix is more favorable than Enanta Pharmaceuticals.
Enanta Pharmaceuticals received 296 more outperform votes than CorMedix when rated by MarketBeat users. However, 70.00% of users gave CorMedix an outperform vote while only 56.47% of users gave Enanta Pharmaceuticals an outperform vote.
Summary
CorMedix beats Enanta Pharmaceuticals on 10 of the 18 factors compared between the two stocks.
Get CorMedix News Delivered to You Automatically
Sign up to receive the latest news and ratings for CRMD and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CRMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
CorMedix Competitors List
Related Companies and Tools
